Reports Q3 revenue $33.899M, consensus $36.1M. "This quarter we reported strong top-line growth and continued to gain market share while carefully managing our operating expenses as we advance toward profitability," said David Moatazedi, President and Chief Executive Officer. "Demand for Jeuveau(R) remained strong even with anticipated seasonality and the return of summer travel. We remain confident we can achieve the top end of our 2022 sales guidance range of $143 to $150 million equating to a year-over-year growth rate of approximately 50%, which is roughly triple the projected toxin market growth rate."
Published first on TheFly
